Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CCR1 antagonists in clinical development.

James E Pease1, Richard Horuk

  • 1Biomedical Sciences Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, South Kensington Campus, London SW7 2AZ, UK. j.pease@imperial.ac.uk

Expert Opinion on Investigational Drugs
|July 19, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for a Two-Step Model for Activation of GPR25 by the Chemoattractant CXCL17.

Basic & clinical pharmacology & toxicology·2026
Same author

SOX17-silenced HPAECs upregulate NF-κB-induced CXCL10 and CXCL11: implications for lymphocyte chemotaxis in SOX17-PAH.

Scientific reports·2025
Same author

The chemokine receptor CCR8 is not a high-affinity receptor for the human chemokine CCL18.

PloS one·2024
Same author

CXCL17 binds efficaciously to glycosaminoglycans with the potential to modulate chemokine signaling.

Frontiers in immunology·2023
Same author

The protease associated (PA) domain in ScpA from Streptococcus pyogenes plays a role in substrate recruitment.

Biochimica et biophysica acta. Proteins and proteomics·2023
Same author

Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.

Journal of clinical medicine·2020

Chemokines are proteins that guide leukocyte movement. Targeting CC chemokine receptor 1 offers potential therapies for inflammatory diseases like rheumatoid arthritis and multiple sclerosis.

Area of Science:

  • Immunology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemokines (chemotactic cytokines) are crucial for leukocyte migration, mediated by G protein-coupled receptors.
  • Aberrant chemokine production is linked to inflammatory diseases, driving research into chemokine-receptor interactions for therapeutic strategies.

Purpose of the Study:

  • To review the biology of CC chemokine receptor 1 (CCR1).
  • To explore CCR1's role in inflammatory conditions such as rheumatoid arthritis, multiple sclerosis, and organ transplant rejection.
  • To highlight therapeutic developments targeting CCR1 and their clinical efficacy.

Main Methods:

  • Literature review focusing on CC chemokine receptor 1.
  • Analysis of studies investigating chemokine-ligand interactions.

Related Experiment Videos

  • Examination of clinical trial data for CCR1 antagonists.

    • Main Results:

    • CC chemokine receptor 1 plays a significant role in recruiting leukocytes in inflammatory diseases.
    • Several antagonists targeting CCR1 have been developed.
    • The clinical efficacy of these CCR1 antagonists is under evaluation.

    Conclusions:

    • CC chemokine receptor 1 is a key target for managing inflammatory conditions.
    • Therapeutic antagonism of CCR1 shows promise for treating rheumatoid arthritis, multiple sclerosis, and transplant rejection.
    • Further clinical investigation is warranted to establish the full therapeutic potential of CCR1 antagonists.